Michael Wolf

Michael Wolf

Auto-generated profile, based on publicly available information

Michael Wolf

Department of Cardiology, Sint-Jan Hospital Bruges, Bruges, Belgium

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2020 in Heart Rhythm
Verified
Journal Article
Closed access
MDMattias Duytschaever
Mattias Duytschaever
JPJan De Pooter
Jan De Pooter
ADAnthony Demolder
Anthony Demolder
MHMilad El Haddad
Milad El Haddad
TPThomas Phlips
Thomas Phlips
RTRene Tavernier
Rene Tavernier

1 September 2019 in Heart Rhythm
Verified
Journal Article
Closed access
KVKonstantinos Vlachos
Konstantinos Vlachos
ADArnaud Denis
Arnaud Denis
MTMasateru Takigawa
Masateru Takigawa
TKTakeshi Kitamura
Takeshi Kitamura
CMClaire A. Martin
Claire A. Martin
NDNicolas Derval
Nicolas Derval

1 November 2019 in Heart Rhythm
Verified
Journal Article
Closed access
MTMasateru Takigawa
Masateru Takigawa
JDJosselin Duchateau
Josselin Duchateau
FSFrederic Sacher
Frederic Sacher
RMRuairidh Martin
Ruairidh Martin
KVKonstantinos Vlachos
Konstantinos Vlachos
PJPierre Jaïs
Pierre Jaïs

1 February 2018 in Circulation: Arrhythmia and Electrophysiology
Verified
Journal Article
Closed access
PDF file
MWMichael Wolf
Michael Wolf
FSFrédéric Sacher
Frédéric Sacher
HCHubert Cochet
Hubert Cochet
TKTakeshi Kitamura
Takeshi Kitamura
MTMasateru Takigawa
Masateru Takigawa
PJPierre Jaïs
Pierre Jaïs
Background: Long-term results of substrate modification for ablation of ventricular tachycardia (VT) have not been reported. We report long-term outcomes of substrate elimination targeting local abnormal ventricular activities (LAVA) for post–myocardial infarction VT. Methods and Results: One hundred fifty-nine consecutive patients undergoing first ablation were included (65±11 years, 92% implantable cardioverter defibrillators, 54% storms, and 73% appropriate shocks). LAVA were identified in 92% and VT was inducible in 73%. Complete LAVA elimination and noninducibility after ablation were achieved in 64% and 85%. During a median follow-up of 47 months (interquartile range, 34–82), single-procedure ventricular arrhythmia (VA)–free survival was 55% (10% storms and 19% shocks). The VA-free survival was 73%, 68%, 61%, 55%, and 49% after 1, 2, 3, 4, and 5 years, respectively. Complete LAVA elimination was associated with improved outcomes: VA-free survival of 82% at 1 year and 61% at 5 years. In the subgroup treated with multielectrode mapping and real-time image integration, VA-free survival was 86% and 65% at 1 year and 4 years, respectively. Including repeat procedures in 18% of pts (1.3±0.6 ablations/pt) outcomes improved to 69% VA-free survival (2% storms and 9% shocks) during median 46-month follow-up. Overall survival was 91% at 1 year and 77% at 5 years of follow-up. Conclusions: In this monocentric study, substrate modification targeting LAVA for post–myocardial infarction VT resulted in a substantial reduction of VT storm and implantable cardioverter defibrillator shocks and up to 49% of patients free from arrhythmia at 5 years after a single procedure. Complete LAVA elimination, multielectrode mapping, and real-time integration were associated with improved VA-free survival.

1 December 2018 in Heart Rhythm
Verified
Journal Article
Closed access
MTMasateru Takigawa
Masateru Takigawa
JRJatin Relan
Jatin Relan
RMRuairidh Martin
Ruairidh Martin
SKSteven Kim
Steven Kim
TKTakeshi Kitamura
Takeshi Kitamura
PJPierre Jaïs
Pierre Jaïs

8 January 2018 in EP Europace
Verified
Journal Article
Closed access
PDF file
MWMichael Wolf
Michael Wolf
MHMilad El Haddad
Milad El Haddad
JFJoël Fedida
Joël Fedida
PTPhilippe Taghji
Philippe Taghji
KBKatarina Van Beeumen
Katarina Van Beeumen
SKSébastien Knecht
Sébastien Knecht
Achieving block across linear lesions is challenging. We prospectively evaluated radiofrequency (RF) linear ablation at the roof and mitral isthmus (MI) using point-by-point contiguous and optimized RF lesions. Forty-one consecutive patients with symptomatic persistent AF underwent stepwise contact force (CF)-guided catheter ablation during ongoing AF. A single linear set of RF lesions was delivered at the roof and posterior MI according to the ‘Atrial LINEar’ (ALINE) criteria, i.e. point-by-point RF delivery (up to 35 W) respecting strict criteria of contiguity (inter-lesion distance ≤ 6 mm) and indirect lesion depth assessment (ablation index ≥550). We assessed the incidence of bidirectional block across both lines only after restoration of sinus rhythm. After a median RF time of 7 min [interquartile range (IQR) 5–9], first-pass block across roof lines was observed in 38 of 41 (93%) patients. Final bidirectional roof block was achieved in 40 of 41 (98%) patients. First-pass block was observed in 8 of 35 (23%) MI lines, after a median RF time of 8 min (IQR 7–12). Additional endo- and epicardial (54% of patients) RF applications resulted in final bidirectional MI block in 28 of 35 (80%) patients. During a median follow-up of 396 (IQR 310–442) days, 12 patients underwent repeat procedures, with conduction recovery in 4 of 12 and 5 of 10 previously blocked roof lines and MI lines, respectively. No complications occurred. Anatomical linear ablation using contiguous and optimized RF lesions results in a high rate of first-pass block at the roof but not at the MI. Due to its complex 3D architecture, the MI frequently requires additional endo- and epicardial RF lesions to be blocked.